Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-10-07

Tempus AI, Inc.

Tempus provides molecular diagnostics, AI-enabled clinical workflow tools, and data and analytics products to physicians, health systems, and biopharma companies.

ai biotech healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated data flywheel with real upside gates

A provider-connected diagnostics and data platform can compound faster than traditional labs if monitoring, workflow, and biopharma monetization scale together. The opportunity is real, but the rerating still depends on approvals, reimbursement, and integration discipline.

Analysis

Thesis

Tempus can compound faster than a normal diagnostics company because every added test, workflow deployment, and biopharma engagement expands a governed clinical data asset that can be monetized again through software, monitoring, and regulated care workflows; if Personalis closes and reimbursement gates clear, revenue quality should improve enough to drive a meaningful rerating by 2031.

Last Economy Alignment

Tempus benefits from cheaper AI because it owns scarce healthcare control points: governed multimodal data, regulated workflow placement, and lab-generated insight. Its software is not mainly seat-priced, switching costs look real, and agent bypass risk is limited by trust, permissioning, and reimbursement gates.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.2x (from 5 most recent analyses)

Reasoning

The upside is mainly a quality-of-revenue story. Core diagnostics should keep growing, but the real rerating comes if MRD, liquid biopsy, biopharma data contracts, and workflow products become a larger share of sales. That would make the business look less like a testing lab and more like a regulated healthcare data-and-execution platform. I still cap the outcome below the best software or MRD leaders because approval, reimbursement, and integration gates remain material.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

Tempus has real assets and real demand, but the five-year upside still depends on a tight sequence: keep diagnostics growth healthy, close and integrate Personalis, scale MRD through a larger sales footprint, win reimbursement and regulatory milestones, and prove that data and workflow revenue becomes more durable and higher quality. If those gates slip, the stock can de-rate faster than revenue slows.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On October 7, 2026, Tempus announced an expanded multi-year collaboration with Moderna and Merck tied to commercialization support for individualized cancer vaccine workflows.
On October 1, 2026, Tempus disclosed 13 accepted ESMO 2026 abstracts, keeping a meaningful near-term data-validation catalyst in front of investors for October 23-27, 2026.
On October 2, 2026, the Tempus-Personalis transaction advanced through an amended S-4 filing, but closing is still pending shareholder and regulatory approvals.
On September 28, 2026, Tempus received FDA clearance for ECG-MR, which modestly strengthens cardiology optionality and regulated AI credibility.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.69

It owns the clinical data, lab outputs, and workflow checkpoints that make AI useful in cancer care, so better models can increase the value of its system. The main threat is not cheap software but delays in approvals, reimbursement, or trust that slow monetization.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$70.06

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research